Therapeutics for autoimmune kidney disease: synthetic antigens

Kira Astakhova (Inventor)

Research output: Patent

9 Downloads (Pure)

Abstract

The present invention concerns therapeutics for autoimmune diseases and provides removal of inflammation-causing autoantibodies. In order to target the disease in the most efficient manner, a nanoconjugate complex is provided, comprising at least one specific antigen component recognized by autoantibodies related to the autoimmune disease, at least one helper moiety, and a nanoparticle carrier connecting the components. Each component of the therapeutic nanoconjugate complex has a specific function, yielding a nanoconjugate complex which facilitates specific binding, forming a stable antibody- therapeutic complex in the blood stream and rapid clearance of this complex to the liver.

Original languageEnglish
IPCA61P 13/ 12 A I
Patent numberWO2019149946
Filing date02/02/2018
CountryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date02/02/2018
Priority numberEP20180154924
Publication statusPublished - 8 Aug 2019

Cite this

Astakhova, K. (2019). IPC No. A61P 13/ 12 A I. Therapeutics for autoimmune kidney disease: synthetic antigens. (Patent No. WO2019149946).
Astakhova, Kira (Inventor). / Therapeutics for autoimmune kidney disease: synthetic antigens. IPC No.: A61P 13/ 12 A I. Patent No.: WO2019149946. Feb 02, 2018.
@misc{b87b9bfb86884b889e782abab888da6d,
title = "Therapeutics for autoimmune kidney disease: synthetic antigens",
abstract = "The present invention concerns therapeutics for autoimmune diseases and provides removal of inflammation-causing autoantibodies. In order to target the disease in the most efficient manner, a nanoconjugate complex is provided, comprising at least one specific antigen component recognized by autoantibodies related to the autoimmune disease, at least one helper moiety, and a nanoparticle carrier connecting the components. Each component of the therapeutic nanoconjugate complex has a specific function, yielding a nanoconjugate complex which facilitates specific binding, forming a stable antibody- therapeutic complex in the blood stream and rapid clearance of this complex to the liver.",
author = "Kira Astakhova",
year = "2019",
month = "8",
day = "8",
language = "English",
type = "Patent",
note = "WO2019149946; A61P 13/ 12 A I",

}

Astakhova, K Feb. 02 2018, Therapeutics for autoimmune kidney disease: synthetic antigens, Patent No. WO2019149946, IPC No. A61P 13/ 12 A I.

Therapeutics for autoimmune kidney disease: synthetic antigens. / Astakhova, Kira (Inventor).

IPC No.: A61P 13/ 12 A I. Patent No.: WO2019149946. Feb 02, 2018.

Research output: Patent

TY - PAT

T1 - Therapeutics for autoimmune kidney disease: synthetic antigens

AU - Astakhova, Kira

PY - 2019/8/8

Y1 - 2019/8/8

N2 - The present invention concerns therapeutics for autoimmune diseases and provides removal of inflammation-causing autoantibodies. In order to target the disease in the most efficient manner, a nanoconjugate complex is provided, comprising at least one specific antigen component recognized by autoantibodies related to the autoimmune disease, at least one helper moiety, and a nanoparticle carrier connecting the components. Each component of the therapeutic nanoconjugate complex has a specific function, yielding a nanoconjugate complex which facilitates specific binding, forming a stable antibody- therapeutic complex in the blood stream and rapid clearance of this complex to the liver.

AB - The present invention concerns therapeutics for autoimmune diseases and provides removal of inflammation-causing autoantibodies. In order to target the disease in the most efficient manner, a nanoconjugate complex is provided, comprising at least one specific antigen component recognized by autoantibodies related to the autoimmune disease, at least one helper moiety, and a nanoparticle carrier connecting the components. Each component of the therapeutic nanoconjugate complex has a specific function, yielding a nanoconjugate complex which facilitates specific binding, forming a stable antibody- therapeutic complex in the blood stream and rapid clearance of this complex to the liver.

M3 - Patent

M1 - WO2019149946

Y2 - 2018/02/02

ER -